# A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

> **NCT04822701** · PHASE2,PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 5 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** BI 767551 intravenous
- **DRUG:** BI 767551 inhaled
- **DRUG:** Placebo intravenous
- **DRUG:** Placebo inhaled

## Key facts

- **NCT ID:** NCT04822701
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-21
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-10-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** not due to safety reasons
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04822701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04822701, "A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04822701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*